Tyrosine News and Research

RSS

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

Stress in adolescence can cause severe mental illness in young adulthood

Working with mice, Johns Hopkins researchers have established a link between elevated levels of a stress hormone in adolescence — a critical time for brain development — and genetic changes that, in young adulthood, cause severe mental illness in those predisposed to it.

18 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

Study: Patients with EGFR exon 20 insertions need targeted therapies

Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

16 Jan 2013

Cancer-associated inflammation boosts ADAR1 enzyme activity

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence.

25 Dec 2012

GI bacteria exert some control over their hosts' appetites: Review

Over the last half decade, it has become increasingly clear that the normal gastrointestinal (GI) bacteria play a variety of very important roles in the biology of human and animals. Now Vic Norris of the University of Rouen, France, and coauthors propose yet another role for GI bacteria: that they exert some control over their hosts' appetites.

20 Dec 2012

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

High-risk leukemia patients respond to novel drug

A third of adult leukemia patients given the novel drug quizartinib during a phase II study have achieved a composite response of either complete remission, or remission with incomplete platelet recovery or incomplete hematologic recovery, report US researchers.

14 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib.

From NanoString Technologies 13 Dec 2012

TKI-resistant human leukemia stem cells are the source of genomic instability

An international team of scientists, led by researchers from Temple University School of Medicine, has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs.

12 Dec 2012

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

RET fusion signals unique NSCLC subtype

The presence of RET fusion genes in approximately 1.5% of non-small-cell lung cancer defines a subset of tumors with distinct clinicopathologic features, research suggests.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.

10 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Tyrosine News and Research

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Stress in adolescence can cause severe mental illness in young adulthood

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Study: Patients with EGFR exon 20 insertions need targeted therapies

Cancer-associated inflammation boosts ADAR1 enzyme activity

GI bacteria exert some control over their hosts' appetites: Review

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Iclusig gets FDA approval for two rare blood and bone marrow diseases

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

High-risk leukemia patients respond to novel drug

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

TKI-resistant human leukemia stem cells are the source of genomic instability

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

RET fusion signals unique NSCLC subtype

Ibrutinib may effectively combat chronic lymphocytic leukemia

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News